GlycoMimetics prices upsized IPO at $8 per share


Shutterstock photo

GlycoMimetics, a clinical-stage biotech developing treatments for sickle cell episodes and AML, raised $56 million by offering 7.0 million shares at $8, the lower revised price. The company upsized its IPO selling 22% more shares than previously anticipated (5.8 million). The company had originally filed to offer 4.0 million shares at a range of $14 to $16 before cutting the deal size Tuesday morning. GlycoMimetics plans to list on the NASDAQ under the symbol GLYC. GlycoMimetics initially filed confidentially on August 21, 2013. Jefferies and Barclays acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by